Any 0 3 0 3 O
known 4 9 4 9 O
history 10 17 10 17 O
of 18 20 18 20 O
Grade 21 26 21 26 B-chronic_disease
4 27 28 27 28 I-chronic_disease
thrombocytopenia 29 45 29 45 I-chronic_disease
with 46 50 46 50 O
any 51 54 51 54 O
prior 55 60 55 60 B-treatment
chemotherapy 61 73 61 73 I-treatment
regimen 74 81 74 81 O

During 0 6 82 88 O
prior 7 12 89 94 O
platinum 13 21 95 103 O
therapy 22 29 104 111 B-treatment
, 29 30 111 112 O
requirement 31 42 113 124 O
for 43 46 125 128 O
dose 47 51 129 133 O
reduction 52 61 134 143 O
or 62 64 144 146 O
discontinuation 65 80 147 162 O
of 81 83 163 165 O
carboplatin 84 95 166 177 B-treatment
or 96 98 178 180 O
cisplatin 99 108 181 190 B-treatment
for 109 112 191 194 O
toxicity 113 121 195 203 O
or 122 124 204 206 O
lack 125 129 207 211 O
of 130 132 212 214 O
tolerability 133 145 215 227 O

Female 0 6 228 234 B-gender
participants 7 19 235 247 I-gender
who 20 23 248 251 O
are 24 27 252 255 O
already 28 35 256 263 O
pregnant 36 44 264 272 B-pregnancy
or 45 47 273 275 O
lactating 48 57 276 285 B-pregnancy
, 57 58 285 286 O
or 59 61 287 289 O
plan 62 66 290 294 B-pregnancy
to 67 69 295 297 I-pregnancy
become 70 76 298 304 I-pregnancy
pregnant 77 85 305 313 I-pregnancy
within 86 92 314 320 O
6 93 94 321 322 B-upper_bound
months 95 101 323 329 I-upper_bound
of 102 104 330 332 O
the 105 108 333 336 O
last 109 113 337 341 O
dose 114 118 342 346 O
of 119 121 347 349 O
study 122 127 350 355 B-treatment
drug 128 132 356 360 I-treatment

Life 0 4 361 365 B-clinical_variable
expectancy 5 15 366 376 I-clinical_variable
of 16 18 377 379 O
> 19 20 380 381 O
= 20 21 381 382 O
12 21 23 382 384 B-lower_bound
weeks 24 29 385 390 I-lower_bound

Major 0 5 391 396 B-treatment
surgery 6 13 397 404 I-treatment
= 14 15 405 406 O
< 15 16 406 407 O
4 16 17 407 408 B-upper_bound
weeks 18 23 409 414 I-upper_bound
before 24 30 415 421 I-upper_bound
first 31 36 422 427 O
dose 37 41 428 432 O
of 42 44 433 435 O
study 45 50 436 441 B-treatment
drug 51 55 442 446 I-treatment
or 56 58 447 449 O
incomplete 59 69 450 460 O
recovery 70 78 461 469 O
from 79 83 470 474 O
a 84 85 475 476 O
prior 86 91 477 482 B-treatment
major 92 97 483 488 I-treatment
surgical 98 106 489 497 I-treatment
procedure 107 116 498 507 I-treatment

Male 0 4 508 512 B-gender
participants 5 17 513 525 I-gender
with 18 22 526 530 O
partners 23 31 531 539 O
of 32 34 540 542 O
childbearing 35 47 543 555 O
potential 48 57 556 565 O
must 58 62 566 570 O
agree 63 68 571 576 B-contraception_consent
to 69 71 577 579 I-contraception_consent
adhere 72 78 580 586 I-contraception_consent
to 79 81 587 589 I-contraception_consent
contraception 82 95 590 603 I-contraception_consent
guidelines 96 106 604 614 O

Men 0 3 615 618 B-gender
with 4 8 619 623 O
pregnant 9 17 624 632 B-pregnancy
or 18 20 633 635 O
lactating 21 30 636 645 O
partners 31 39 646 654 O
or 40 42 655 657 O
partners 43 51 658 666 O
who 52 55 667 670 O
plan 56 60 671 675 B-pregnancy
to 61 63 676 678 I-pregnancy
become 64 70 679 685 I-pregnancy
pregnant 71 79 686 694 I-pregnancy
during 80 86 695 701 O
the 87 90 702 705 O
study 91 96 706 711 O
or 97 99 712 714 O
within 100 106 715 721 O
6 107 108 722 723 B-upper_bound
months 109 115 724 730 I-upper_bound
of 116 118 731 733 O
the 119 122 734 737 O
last 123 127 738 742 O
dose 128 132 743 747 O
of 133 135 748 750 O
study 136 141 751 756 B-treatment
drug 142 146 757 761 I-treatment

More 0 4 762 766 O
than 5 9 767 771 O
6 10 11 772 773 B-lower_bound
cycles 12 18 774 780 O
of 19 21 781 783 O
prior 22 27 784 789 B-treatment
therapy 28 35 790 797 I-treatment
with 36 40 798 802 I-treatment
carboplatin 41 52 803 814 I-treatment

Ongoing 0 7 815 822 O
toxic 8 13 823 828 O
manifestations 14 28 829 843 O
of 29 31 844 846 O
previous 32 40 847 855 B-treatment
treatments 41 51 856 866 I-treatment

Participants 0 12 867 879 O
with 13 17 880 884 O
advanced 18 26 885 893 O
( 27 28 894 895 O
locally 28 35 895 902 O
advanced 36 44 903 911 O
incurable 45 54 912 921 O
or 55 57 922 924 O
metastatic 58 68 925 935 B-cancer
) 68 69 935 936 O
histologically 70 84 937 951 O
or 85 87 952 954 O
cytologically 88 101 955 968 O
confirmed 102 111 969 978 O
high 112 116 979 983 B-cancer
- 116 117 983 984 I-cancer
grade 117 122 984 989 I-cancer
serous 123 129 990 996 I-cancer
ovarian 130 137 997 1004 I-cancer
cancer 138 144 1005 1011 I-cancer
( 145 146 1012 1013 O
high 146 150 1013 1017 O
nuclear 151 158 1018 1025 O
Grades 159 165 1026 1032 O
2 166 167 1033 1034 O
or 168 170 1035 1037 O
3 171 172 1038 1039 O
) 172 173 1039 1040 O
. 173 174 1040 1041 O
Participants 175 187 1042 1054 O
should 188 194 1055 1061 O
have 195 199 1062 1066 O
either 200 206 1067 1073 O
platinum 207 215 1074 1082 B-cancer
- 215 216 1082 1083 I-cancer
refractory 216 226 1083 1093 I-cancer
( 227 228 1094 1095 O
disease 228 235 1095 1102 O
progression 236 247 1103 1114 O
during 248 254 1115 1121 O
initial 255 262 1122 1129 O
platinum 263 271 1130 1138 B-treatment
therapy 272 279 1139 1146 I-treatment
) 279 280 1146 1147 O
or 281 283 1148 1150 O
platinum 284 292 1151 1159 B-cancer
- 292 293 1159 1160 I-cancer
resistant 293 302 1160 1169 I-cancer
( 303 304 1170 1171 O
disease 304 311 1171 1178 O
progression 312 323 1179 1190 O
< 324 325 1191 1192 O
6 325 326 1192 1193 B-upper_bound
months 327 333 1194 1200 I-upper_bound
after 334 339 1201 1206 I-upper_bound
completion 340 350 1207 1217 O
of 351 353 1218 1220 O
platinum 354 362 1221 1229 O
therapy 363 370 1230 1237 O
) 370 371 1237 1238 O
disease 372 379 1239 1246 O

Participants 0 12 1247 1259 O
with 13 17 1260 1264 O
one 18 21 1265 1268 O
histologically 22 36 1269 1283 O
or 37 39 1284 1286 O
cytologically 40 53 1287 1300 O
confirmed 54 63 1301 1310 O
malignant 64 73 1311 1320 B-cancer
advanced 74 82 1321 1329 I-cancer
solid 83 88 1330 1335 I-cancer
tumor 89 94 1336 1341 I-cancer
, 94 95 1341 1342 O
for 96 99 1343 1346 O
which 100 105 1347 1352 O
no 106 108 1353 1355 O
standard 109 117 1356 1364 B-treatment
therapy 118 125 1365 1372 I-treatment
is 126 128 1373 1375 O
available 129 138 1376 1385 O
which 139 144 1386 1391 O
may 145 148 1392 1395 O
convey 149 155 1396 1402 O
clinical 156 164 1403 1411 O
benefit 165 172 1412 1419 O

Participants 0 12 1420 1432 O
with 13 17 1433 1437 O
one 18 21 1438 1441 O
histologically 22 36 1442 1456 O
or 37 39 1457 1459 O
cytologically 40 53 1460 1473 O
confirmed 54 63 1474 1483 O
malignant 64 73 1484 1493 O
advanced 74 82 1494 1502 O
solid 83 88 1503 1508 B-cancer
tumor 89 94 1509 1514 I-cancer
, 94 95 1514 1515 O
for 96 99 1516 1519 O
which 100 105 1520 1525 O
no 106 108 1526 1528 O
standard 109 117 1529 1537 B-treatment
therapy 118 125 1538 1545 I-treatment
is 126 128 1546 1548 O
available 129 138 1549 1558 O
which 139 144 1559 1564 O
may 145 148 1565 1568 O
convey 149 155 1569 1575 O
clinical 156 164 1576 1584 O
benefit 165 172 1585 1592 O
and/or 173 179 1593 1599 O
participants 180 192 1600 1612 O
must 193 197 1613 1617 O
have 198 202 1618 1622 O
progressed 203 213 1623 1633 O
after 214 219 1634 1639 O
at 220 222 1640 1642 O
least 223 228 1643 1648 O
1 229 230 1649 1650 B-lower_bound
prior 231 236 1651 1656 B-treatment
chemotherapy 237 249 1657 1669 I-treatment
regimen 250 257 1670 1677 I-treatment
in 258 260 1678 1680 O
the 261 264 1681 1684 O
metastatic 265 275 1685 1695 O
setting 276 283 1696 1703 O
, 283 284 1703 1704 O
and 285 288 1705 1708 O
for 289 292 1709 1712 O
which 293 298 1713 1718 O
carboplatin 299 310 1719 1730 B-treatment
( 311 312 1731 1732 O
for 312 315 1732 1735 O
Part 316 320 1736 1740 O
B1 321 323 1741 1743 O
) 323 324 1743 1744 O
, 324 325 1744 1745 O
gemcitabine 326 337 1746 1757 B-treatment
( 338 339 1758 1759 O
for 339 342 1759 1762 O
Part 343 347 1763 1767 O
B2 348 350 1768 1770 O
) 350 351 1770 1771 O
, 351 352 1771 1772 O
or 353 355 1773 1775 O
cisplatin 356 365 1776 1785 B-treatment
( 366 367 1786 1787 O
for 367 370 1787 1790 O
Part 371 375 1791 1795 O
B3 376 378 1796 1798 O
) 378 379 1798 1799 O
would 380 385 1800 1805 O
be 386 388 1806 1808 O
considered 389 399 1809 1819 O
standard 400 408 1820 1828 O
of 409 411 1829 1831 O
care 412 416 1832 1836 O

Radiotherapy 0 12 1837 1849 B-treatment
, 12 13 1849 1850 O
unless 14 20 1851 1857 O
brief 21 26 1858 1863 O
course 27 33 1864 1870 O
for 34 37 1871 1874 O
palliative 38 48 1875 1885 B-treatment
therapy 49 56 1886 1893 I-treatment
, 56 57 1893 1894 O
endocrine 58 67 1895 1904 B-treatment
therapy 68 75 1905 1912 I-treatment
, 75 76 1912 1913 O
target 77 83 1914 1920 B-treatment
- 83 84 1920 1921 I-treatment
specific 84 92 1921 1929 I-treatment
therapy 93 100 1930 1937 I-treatment
, 100 101 1937 1938 O
immunotherapy 102 115 1939 1952 B-treatment
, 115 116 1952 1953 O
or 117 119 1954 1956 O
chemotherapy 120 132 1957 1969 B-treatment
during 133 139 1970 1976 O
the 140 143 1977 1980 O
4 144 145 1981 1982 B-lower_bound
weeks 146 151 1983 1988 I-lower_bound
( 152 153 1989 1990 O
6 153 154 1990 1991 B-lower_bound
weeks 155 160 1992 1997 I-lower_bound
for 161 164 1998 2001 O
nitrosoureas 165 177 2002 2014 B-treatment
and 178 181 2015 2018 O
Mitomycin 182 191 2019 2028 B-treatment
- 191 192 2028 2029 I-treatment
C 192 193 2029 2030 I-treatment
, 193 194 2030 2031 O
and 195 198 2032 2035 O
4 199 200 2036 2037 O
weeks 201 206 2038 2043 O
for 207 210 2044 2047 O
investigational 211 226 2048 2063 O
medicinal 227 236 2064 2073 O
products 237 245 2074 2082 O
) 245 246 2082 2083 O
or 247 249 2084 2086 O
4 250 251 2087 2088 O
drug 252 256 2089 2093 O
half 257 261 2094 2098 O
- 261 262 2098 2099 O
lives 262 267 2099 2104 O
before 268 274 2105 2111 O
first 275 280 2112 2117 O
dose 281 285 2118 2122 O
of 286 288 2123 2125 O
study 289 294 2126 2131 B-treatment
drug 295 299 2132 2136 I-treatment
, 299 300 2136 2137 O
whichever 301 310 2138 2147 O
is 311 313 2148 2150 O
greater 314 321 2151 2158 O

Serious 0 7 2159 2166 O
co 8 10 2167 2169 O
- 10 11 2169 2170 O
morbid 11 17 2170 2176 O
medical 18 25 2177 2184 B-chronic_disease
conditions 26 36 2185 2195 I-chronic_disease
, 36 37 2195 2196 O
including 38 47 2197 2206 O
clinically 48 58 2207 2217 O
- 58 59 2217 2218 O
significant 59 70 2218 2229 O
cardiac 71 78 2230 2237 O
disease 79 86 2238 2245 O

Spinal 0 6 2246 2252 B-chronic_disease
cord 7 11 2253 2257 I-chronic_disease
compression 12 23 2258 2269 I-chronic_disease
or 24 26 2270 2272 O
brain 27 32 2273 2278 B-cancer
metastases 33 43 2279 2289 I-cancer
unless 44 50 2290 2296 O
asymptomatic 51 63 2297 2309 O
, 63 64 2309 2310 O
treated 65 72 2311 2318 O
, 72 73 2318 2319 O
stable 74 80 2320 2326 O
, 80 81 2326 2327 O
and 82 85 2328 2331 O
not 86 89 2332 2335 O
requiring 90 99 2336 2345 O
steroids 100 108 2346 2354 B-treatment
for 109 112 2355 2358 O
at 113 115 2359 2361 O
least 116 121 2362 2367 O
4 122 123 2368 2369 B-lower_bound
weeks 124 129 2370 2375 I-lower_bound
before 130 136 2376 2382 I-lower_bound
first 137 142 2383 2388 B-treatment
dose 143 147 2389 2393 I-treatment
of 148 150 2394 2396 I-treatment
study 151 156 2397 2402 I-treatment
drug 157 161 2403 2407 I-treatment

WHO 0 3 2408 2411 B-clinical_variable
performance 4 15 2412 2423 I-clinical_variable
status 16 22 2424 2430 I-clinical_variable
of 23 25 2431 2433 O
0 26 27 2434 2435 B-lower_bound
or 28 30 2436 2438 O
1 31 32 2439 2440 B-upper_bound

